What are the common and serious adverse drug reactions of Zofran (ondansetron) and how should they be managed?

Ondansetron Adverse Drug Reactions and Management

Common Adverse Drug Reactions

The most common adverse reactions to ondansetron are headache (11-24%), constipation (9%), and diarrhea (4-15%), with an overall adverse event incidence of approximately 36-45% in adults receiving chemotherapy. 1, 2, 3

Gastrointestinal Effects

• Constipation occurs in approximately 9% of patients receiving ondansetron for moderately emetogenic chemotherapy 1
• Diarrhea is reported in 4-15% of patients, with higher rates in those receiving chemotherapy 1, 2
• These gastrointestinal effects are generally mild and self-limiting 2, 3

Neurological Effects

• Headache is the most frequently reported adverse reaction, occurring in 11-25% of patients depending on dose and indication 1, 2
• The incidence increases slightly with higher single doses (25% with 32 mg vs 18% with 8 mg) 2
• Malaise/fatigue occurs in approximately 13% of patients 1

Hepatic Effects

• Transient transaminase elevations (AST/ALT exceeding twice the upper limit of normal) occur in 1-2% of patients receiving ondansetron with cyclophosphamide-based chemotherapy 1
• These elevations are typically transient and not dose-related 1
• The role of concurrent chemotherapy in these changes is unclear, and symptomatic hepatic disease rarely occurs 1

---

Serious Adverse Drug Reactions

QT Prolongation and Cardiac Arrhythmias

QT interval prolongation is the most clinically significant serious adverse reaction, with postmarketing reports of Torsade de Pointes, though arrhythmias associated with single oral doses are extremely rare. 1, 4

Risk Factors and Monitoring

• Avoid ondansetron entirely in patients with congenital long QT syndrome 1
• ECG monitoring is recommended for patients with electrolyte abnormalities (hypokalemia, hypomagnesemia), congestive heart failure, bradyarrhythmias, or those taking other QT-prolonging medications 1
• Special caution in pediatric patients with underlying heart disease due to QT prolongation risk 5, 6, 7

Evidence Context

• A systematic review found no reports of arrhythmias associated with single oral ondansetron doses 4
• When arrhythmias occurred, 80% involved intravenous administration, and 83% of cases had significant medical history or concomitant QT-prolonging medications 4
• Routine ECG screening is not supported for single oral doses in patients without known risk factors 4

Drug Interactions Increasing Cardiac Risk

• Contraindicated or requires extreme caution with doses >8 mg when combined with other QT-prolonging agents including certain antineoplastics (cabozantinib, ceritinib, crizotinib, nilotinib, osimertinib, vandetanib), antidepressants (citalopram, escitalopram), and domperidone 8
• Replace domperidone with metomimazine when ondansetron is necessary 8

Serotonin Syndrome

Serotonin syndrome is a potentially fatal adverse reaction that can occur with ondansetron alone (particularly in overdose) but is most commonly associated with concomitant use of serotonergic drugs. 1

Clinical Presentation

• Mental status changes (agitation, hallucinations, delirium, coma) 1
• Autonomic instability (tachycardia, labile blood pressure, diaphoresis, flushing, hyperthermia) 1
• Neuromuscular symptoms (tremor, rigidity, myoclonus, hyperreflexia, incoordination) 1
• Seizures, with or without gastrointestinal symptoms 1

High-Risk Drug Combinations

• SSRIs and SNRIs (citalopram, escitalopram, fluoxetine, paroxetine, sertraline, venlafaxine, duloxetine) 1
• Tricyclic antidepressants (amitriptyline, doxepin, imipramine) 1
• MAO inhibitors (selegiline, phenelzine) 1
• Other serotonergic agents (fentanyl, tramadol, lithium, mirtazapine, intravenous methylene blue) 1

Management

• Discontinue ondansetron immediately if serotonin syndrome is suspected 1
• Initiate supportive treatment promptly 1
• Most reports occurred in post-anesthesia care units or infusion centers 1

Myocardial Ischemia

Myocardial ischemia has been reported with ondansetron, with coronary artery spasm appearing to be the most common underlying mechanism. 1

• Symptoms may appear immediately after administration, predominantly with intravenous use 1
• Monitor or advise patients for signs/symptoms of myocardial ischemia even after oral administration 1
• Symptoms typically resolve with prompt treatment 1

Hypersensitivity Reactions

Anaphylaxis and bronchospasm have been reported, though they are rare (<2% incidence). 1

• Other hypersensitivity manifestations include rash (approximately 1%) 1
• Angina and vascular occlusive events have been reported but causality is unclear 1

---

Special Population Considerations

Pregnancy

• Ondansetron should not be used as first-line therapy during the first trimester due to potential risk of congenital cardiac defects 5, 6
• The American Gastroenterological Association recommends case-by-case use before 10 weeks of gestation 6
• Should only be administered as second-line therapy in early pregnancy 6

Pediatric Patients

• Overall adverse event incidence in pediatric patients is lower (19%) compared to adults 2
• Headache is the most common adverse event (4%) in children 2
• Screen for cardiac history (congenital heart disease, arrhythmias) before administration 7
• Only use in children ≥6 months of age for acute gastroenteritis 7

Postoperative and Gastrointestinal Surgery Patients

• Ondansetron may mask progressive ileus and gastric distension in patients following abdominal surgery or with chemotherapy-induced nausea 1
• Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction 1
• Ondansetron does not stimulate gastric or intestinal peristalsis and should not replace nasogastric suction 1

---

Critical Management Principles

When to Avoid Ondansetron

• Congenital long QT syndrome (absolute contraindication) 1
• Suspected inflammatory diarrhea or diarrhea with fever 5
• Bloody diarrhea or suspected bacterial gastroenteritis 5
• First trimester of pregnancy (avoid as first-line) 5, 6

Monitoring Requirements

• ECG monitoring for high-risk cardiac patients (electrolyte abnormalities, heart failure, bradyarrhythmias, concurrent QT-prolonging drugs) 1
• Electrolyte monitoring particularly for potassium and magnesium in at-risk patients 8, 1
• Bowel activity monitoring in postoperative patients or those at risk for ileus 1
• Serotonin syndrome surveillance when used with serotonergic medications 1

Common Clinical Pitfalls

• Do not use ondansetron as a substitute for proper fluid and electrolyte therapy—it is adjunctive only 5, 7
• Do not delay rehydration while administering ondansetron; these are complementary interventions 5
• Do not overlook drug interactions with serotonergic agents or QT-prolonging medications 8, 1
• Do not use in children under 4 years as first-line—focus on proper oral rehydration solution technique instead 5
• Do not ignore cardiac risk factors before prescribing, especially in pediatric patients with heart disease 5, 6, 7

Tolerability Profile

• Ondansetron is generally better tolerated than metoclopramide with lower incidence of extrapyramidal reactions 2, 3
• Extrapyramidal symptoms occurred in 5% of metoclopramide patients but essentially none with ondansetron in comparative trials 2
• Only isolated case reports of extrapyramidal reactions exist for ondansetron 1, 9